Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Insmed Q4 2023 Adj EPS $(1.28) Misses $(1.15) Estimate, Sales $83.70M Beat $82.76M Estimate

Author: Benzinga Newsdesk | February 22, 2024 08:03am
Insmed (NASDAQ:INSM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. The company reported quarterly sales of $83.70 million which beat the analyst consensus estimate of $82.76 million by 1.14 percent. This is a 41.15 percent increase over sales of $59.30 million the same period last year.

Posted In: INSM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist